The Syk Inhibitor Fostamatinib Decreases the Severity of Colonic Mucosal Damage in a Rodent Model of Colitis

Basit Öğe Kaydı
dc.authoridKARACA, Turan/0000-0002-2500-7781
dc.authoridCan, Hatice/0000-0002-6054-9244;
dc.authorwosidKARACA, Turan/ABD-6669-2020
dc.authorwosiddemirtaş, selim/JED-6784-2023
dc.authorwosidCAN, GÜRAY/AAA-3274-2020
dc.authorwosidCan, Hatice/ABI-7678-2020
dc.authorwosidKurt, Mevlut/Q-2093-2015
dc.contributor.authorCan, Guray
dc.contributor.authorAyvaz, Suleyman
dc.contributor.authorCan, Hatice
dc.contributor.authorDemirtas, Selim
dc.contributor.authorAksit, Hasan
dc.contributor.authorYilmaz, Bulent
dc.contributor.authorKorkmaz, Ugur
dc.date.accessioned2024-06-12T10:50:20Z
dc.date.available2024-06-12T10:50:20Z
dc.date.issued2015
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground and aims: Inflammatory bowel disease is a chronic inflammatory disease of the gastrointestinal system. In some cases, current medications used for inflammatory bowel disease may not be enough for remission, creating a need for more potent and reliable medications. There is no study showing the efficacy of fostamatinib, with proven effects on some inflammatory diseases, on ulcerative colitis. In our study we planned to research the efficacy of fostamatinib, a spleen tyrosine kinase inhibitor, on acetic acid-induced colitis. Methods: The study included 28 male Sprague-Dawley rats, randomly divided into control group, fostamatinib group, colitis group and fostamatinib + colitis group, each containing seven rats. Colitis induction was performed with 4% acetic acid. Colonic inflammation was assessed with disease activity index, macroscopic and histological damage scores, colonic myeloperoxidase, malondialdehyde and superoxide dismutase activity, and tumour necrosis factor alpha [TNF alpha], CD3, Syk, and phospho-Syk expression. Results: There was a significant difference between the colitis and control groups in terms of all parameters. The disease activity index, macroscopic and microscopic damage scores, immunohistochemical TNF alpha, CD3, Syk, and phospho-Syk expression, and tissue myeloperoxidase activity were found to be significantly lower in the colitis + fostamatinib group compared with the colitis group. There was no significant difference between the two groups in terms of myeloperoxidase and malondialdehyde activity. Conclusions: Fostamatinib reduced the inflammatory damage in the experimental colitis. This effect may be due to suppression of TNF alpha, T-lymphocytes, and neutrophils in colonic mucosa via suppression of Syk. Fostamatinib may be an appropriate treatment alternative for ulcerative colitis. Further clinical studies are required to support this.en_US
dc.identifier.doi10.1093/ecco-jcc/jjv114
dc.identifier.endpage917en_US
dc.identifier.issn1873-9946
dc.identifier.issn1876-4479
dc.identifier.issue10en_US
dc.identifier.pmid26116555en_US
dc.identifier.scopus2-s2.0-84981173520en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage907en_US
dc.identifier.urihttps://doi.org/10.1093/ecco-jcc/jjv114
dc.identifier.urihttps://hdl.handle.net/20.500.14551/17968
dc.identifier.volume9en_US
dc.identifier.wosWOS:000362963300012en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherOxford Univ Pressen_US
dc.relation.ispartofJournal Of Crohns & Colitisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAcetic Acid-Induced Colitisen_US
dc.subjectFostamatiniben_US
dc.subjectRatsen_US
dc.subjectSpleen Tyrosine Kinaseen_US
dc.subjectInflammatory-Bowel-Diseaseen_US
dc.subjectSpleen Tyrosine Kinaseen_US
dc.subjectTumor-Necrosis-Factoren_US
dc.subjectAcid-Induced Colitisen_US
dc.subjectUlcerative-Colitisen_US
dc.subjectCrohns-Diseaseen_US
dc.subjectSuperoxide-Dismutaseen_US
dc.subjectPeripheral-Blooden_US
dc.subjectRat Modelen_US
dc.subjectCellsen_US
dc.titleThe Syk Inhibitor Fostamatinib Decreases the Severity of Colonic Mucosal Damage in a Rodent Model of Colitisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu